Autopsy report · NCT00690846

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

“Dr. Jorizzo has withdrawn from this study due to time it is taking to start”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Pyoderma Gangrenosum

Interventions

adalimumab

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
  “This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.” (59% match in meaning)
• Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
  “Study was terminated early due to lack of experimental medication (supply issues)” (58% match in meaning)
• Characteristic Analysis and Surgical Exploration for Acetabular Roof Fractures: Multicenter Retrospective Cohort Study
  “Due to limited funding, the study is now being withdrawn.” (58% match in meaning)
• Medication Use Among American Indians Adults
  “The study has not been stopped. The study does not qualify as a clinical trial so it was withdrawn from clinicaltrials.gov.” (58% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.